Strategic Collaboration Agreement Signed with Lilly TuneLab

"Expanding Global AI Drug Discovery Collaboration Opportunities"

Pharos iBio, an artificial intelligence (AI) drug discovery company, announced on June 9 that it has signed a strategic participation and collaboration agreement with Eli Lilly’s drug development platform, Lilly TuneLab.


This collaboration aims to advance Pharos iBio’s AI drug discovery platform, Chemiverse, by connecting its accumulated expertise in candidate compound discovery and clinical development to the AI/machine learning (ML)-based drug development system of this global pharmaceutical leader.

Pharos iBio Joins Eli Lilly’s Global AI Drug Discovery Ecosystem View original image

Through this partnership, Pharos iBio plans to further advance the Chemiverse platform, accelerate pipeline development, and enhance the probability of success, ultimately strengthening its global competitiveness.The company will utilize candidate compounds and development strategies identified through Chemiverse and integrate them with Lilly TuneLab’s AI/ML predictive environment to comprehensively evaluate key pipeline properties, drug characteristics, and development feasibility from multiple perspectives.



This collaboration is significant in that it aims to overcome the limitations faced by biotech companies, which have traditionally required extensive time and substantial investment to build AI/ML infrastructure and large-scale big data. It will validate the success potential and development feasibility of candidate compound discovery and clinical development expertise secured through Pharos iBio’s proprietary platform within a global collaborative framework. A company representative stated, “Based on the data and development experience obtained through Chemiverse, we will continue to expand global AI drug discovery collaboration opportunities.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing